Cited 0 times in
Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2024-05-30T07:11:38Z | - |
dc.date.available | 2024-05-30T07:11:38Z | - |
dc.date.issued | 2023-03 | - |
dc.identifier.issn | 1099-5129 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/199629 | - |
dc.description.abstract | Aims Reactive atrial-based anti-tachycardia pacing (rATP) in pacemakers (PMs) and cardiac resynchronization therapy defibrillators (CRT-Ds) has been reported to prevent progression of atrial fibrillation, and this reduced progression is expected to decrease the risk of complications such as stroke and heart failure (HF). This study aimed to assess the cost-effectiveness of rATP in PMs and CRT-Ds in the Japanese public health insurance system. Methods and results We developed a Markov model comprising five states: bradycardia, post-stroke, mild HF, severe HF, and death. For devices with rATP and control devices without rATP, we compared the incremental cost-effectiveness ratio (ICER) from the payer's perspective. Costs were estimated from healthcare resource utilisation data in a Japanese claims database. We evaluated model uncertainty by analysing two scenarios for each device. The ICER was 763 729 JPY/QALY (5616 EUR/QALY) for PMs and 1,393 280 JPY/QALY (10 245 EUR/QALY) for CRT-Ds. In all scenarios, ICERs were below 5 million JPY/QALY (36 765 EUR/QALY), supporting robustness of the results. Conclusion According to a willingness to pay threshold of 5 million JPY/QALY, the devices with rATP were cost-effective compared with control devices without rATP, showing that the higher reimbursement price of the functional categories with rATP is justified from a healthcare economic perspective. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | EUROPACE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Atrial Fibrillation* / complications | - |
dc.subject.MESH | Atrial Fibrillation* / therapy | - |
dc.subject.MESH | Bradycardia / therapy | - |
dc.subject.MESH | Cardiac Resynchronization Therapy* / adverse effects | - |
dc.subject.MESH | Cost-Benefit Analysis | - |
dc.subject.MESH | Cost-Effectiveness Analysis | - |
dc.subject.MESH | Heart Failure* / complications | - |
dc.subject.MESH | Heart Failure* / prevention & control | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Quality-Adjusted Life Years | - |
dc.title | Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Others | - |
dc.contributor.googleauthor | Takashi Noda | - |
dc.contributor.googleauthor | Nobuhiko Ueda | - |
dc.contributor.googleauthor | Yuji Tanaka | - |
dc.contributor.googleauthor | Yoko Ishiguro | - |
dc.contributor.googleauthor | Tomoko Matsumoto | - |
dc.contributor.googleauthor | Tatsuhiro Uenishi | - |
dc.contributor.googleauthor | Hiroko Yamaguchi | - |
dc.contributor.googleauthor | Ayako Shoji | - |
dc.contributor.googleauthor | Jae-Eun Myung | - |
dc.contributor.googleauthor | Kengo Kusano | - |
dc.identifier.doi | 10.1093/europace/euad003 | - |
dc.relation.journalcode | J00801 | - |
dc.identifier.eissn | 1532-2092 | - |
dc.identifier.pmid | 36691793 | - |
dc.subject.keyword | Atrial anti-tachycardia pacing | - |
dc.subject.keyword | Atrial fibrillation | - |
dc.subject.keyword | Cardiac resynchronization therapy | - |
dc.subject.keyword | Cost-effectiveness | - |
dc.subject.keyword | Heart failure | - |
dc.subject.keyword | Pacemaker | - |
dc.citation.volume | 25 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 1087 | - |
dc.citation.endPage | 1099 | - |
dc.identifier.bibliographicCitation | EUROPACE, Vol.25(3) : 1087-1099, 2023-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.